Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes
- 3.1k Downloads
Aplastic anemia is a bone marrow failure syndrome that causes pancytopenia and can lead to life-threatening complications. Bone marrow transplantation remains the standard of care for younger patients and those with a good performance status but many patients may not have a suitable donor. Immunosuppressive therapy is able to resolve cytopenias in a majority of patients with aplastic anemia but relapses are not uncommon and some patients remain refractory to this approach. Patients may require frequent blood and platelet transfusion support which is expensive and inconvenient. Life-threatening bleeding complications still occur despite prophylactic platelet transfusion. Thrombopoietin (TPO) mimetics, such as romiplostim and eltrombopag, were developed to treat patients with refractory immune thrombocytopenia but are now being investigated for the treatment of bone marrow failure syndromes. TPO is the main regulator for platelet production and its receptor (c-Mpl) is present on megakaryocytes and hematopoietic stem cells. Trilineage hematopoietic responses were observed in a recent clinical trial using eltrombopag in patients with severe aplastic anemia refractory to immunosuppression suggesting that these agents can provide a new therapeutic option for enhancing blood production. In this review, we discuss these recent results and ongoing investigation of TPO mimetics for aplastic anemia and other bone marrow failure states like myelodysplastic syndromes. Clonal evolution or progression to acute myeloid leukemia remains a concern when using these drugs in bone marrow failure and patients should only be treated in the setting of a clinical trial.
KeywordsAplastic anemia Eltrombopag Thrombopoietin (TPO) mimetics Bone marrow failure Thrombocytopenia Myelodysplastic syndromes (MDS)
Aplastic anemia is a rare, life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow. Most cases are due to autoimmune attack of marrow stem and progenitor cells leading to pancytopenia . Allogeneic bone marrow transplantation offers the opportunity for cure in younger patients, but most are not suitable candidates for transplantation due to advanced age or lack of a histocompatible donor. Comparable long-term survival in severe aplastic anemia is attainable with standard immunosuppressive treatment (IST). However, of those patients treated with IST, one-quarter to one-third will not respond, and 30–40 % of responders relapse. These patients can have persistent thrombocytopenia, require regular platelet transfusions, which are expensive and inconvenient, and are at risk for further serious bleeding complications.
Pathophysiology of thrombocytopenia in aplastic anemia
Thrombocytopenia is a major cause of morbidity and mortality in patients with aplastic anemia. At presentation, virtually all patients with aplastic anemia are thrombocytopenic: platelet counts of <50,000 or 20,000/μL are diagnostic criteria for moderate and severe aplastic anemia, respectively. Decreased hematopoietic stem and progenitor cell numbers and function, resulting in impaired megakaryocytopoiesis and insufficient mature platelet production, are the causes of thrombocytopenia.
The clinical efficacy of immunosuppression and much laboratory data suggest that the ultimate mechanism leading to hematopoietic stem and progenitor depletion is immune-mediated attack and destruction [1, 2]. The frequency of the most primitive hematopoietic cells is profoundly decreased and, even with clinical response to immunosuppressive therapy, can remain persistently low, as reflected by studies utilizing long-term culture-initiating cells (LT-ICs) and cobblestone formation. Stem cell numbers are markedly diminished and transcriptome analysis demonstrates a pro-apoptotic profile for CD34+ cells from aplastic anemia patients compared to healthy controls, signifying stem cells under stress 3, 4]. This severely diminished population of stem cells subsequently leads to a paucity of megakaryocytes capable of producing platelets.
Clinical consequences of thrombocytopenia
Thrombocytopenia in aplastic anemia causes bleeding, usually petechiae and ecchymoses of the skin and mucous membranes, epistaxis and gingival hemorrhage. Bleeding is not typically observed until the platelet count falls below 10–20,000/μL. Life-threatening bleeding can occur in the presence of accompanying physical lesions related to the underlying aplastic anemia or treatment with immunosuppression, such as corticosteroid-related gastritis, or neutropenia-related fungal infection of the lungs [5, 6]. Intracranial hemorrhage is most feared, as this complication can be life threatening or severely debilitating if not promptly treated . Introduction of routine platelet transfusions in patients with aplastic anemia led to a clear reduction of bleeding complications. Yet, even in the modern era when platelet transfusions are widely used both prophylactically and therapeutically, in long-term follow-up studies as many as 10 % of patients presenting with aplastic anemia still eventually die of bleeding . There is also evidence for asymptomatic hemorrhage, such as cerebral microbleeds, although their clinical significance is currently unknown .
Treatment of thrombocytopenia
The main treatment for thrombocytopenia related to bone marrow failure has been platelet transfusion support, while awaiting a response to IST or engraftment following allogeneic stem cell transplantation. Months typically are required for platelet counts to respond following IST, and time from diagnosis to a sibling or particularly a matched unrelated transplant can be even longer. Routine practice is to provide prophylactic platelet transfusions to avoid significant bleeding in these intervals. Most guidelines recommend transfusing patients with thrombocytopenia prophylactically when platelets fall to <10,000/μL, or in patients with fevers or a bleeding history, <20,000/μL . However, it is important to realize that the clinical evidence supporting transfusion thresholds was gathered primarily from patients with hematologic malignancies undergoing chemotherapy or stem cell transplantation, not aplastic anemia, and these thresholds remain controversial.
Using these thresholds for transfusion typically requires patients to receive transfusions once or twice weekly due to the short half-life of platelets. The frequency of transfusions is dependent on the residual platelet production, the half-life of the platelets transfused, and whether the patient is significantly alloimmunized. Splenomegaly and platelet sequestration are not generally a problem in AA. Prior to the introduction of leukocyte-depleted blood products in the 1980s, a significant proportion of patients developed HLA alloimmunization and became refractory to platelet transfusions. In addition, studies demonstrated that the number of pre-transplant transfusions was associated with an increased risk of graft failure  and death  following hematopoietic stem cell transplant. Since the introduction of universal leukoreduction of blood products, the incidence of HLA alloimmunization appears to be low, although there are no formal studies in AA. In the trial to reduce alloimmunization to platelets (TRAP), patients with acute myelogenous leukemia (AML) were less likely to become refractory to platelet transfusions if they received filtered apheresis platelets . However, it is our experience that even patients with alloimmunization and severe thrombocytopenia can survive without catastrophic bleeding for many years with HLA-matched platelets.
Hematopoietic growth factors
The clinical trials of hematopoietic growth factors, mainly erythropoietic-stimulating agents (ESAs) and G-CSF and also GM-CSF and IL-3, to treat aplastic anemia have been disappointing. There is little rationale for use of cytokines that act on committed hematopoietic progenitors in specific differentiated lineages. First, since receptors for these cytokines are not present on primitive stem cells, and progenitors and lineage-committed precursors able to respond are missing or profoundly reduced, treatment at best might be expected to shorten time to recovery of blood counts following therapy, once immunosuppression or transplantation allows some recovery of stem cell numbers. Second, endogenous erythropoietin and G-CSF levels are extremely elevated in SAA [14, 15]. Whereas in myelodysplastic syndrome (MDS), low endogenous levels of erythropoietin are present in a small proportion of patients but predict responsiveness to ESAs [16, 17]. Clinical trials have examined GM-CSF, G-CSF, stem cell factor (SCF) and IL-3, as single agents or added to standard immunosuppressive therapy for aplastic anemia. In this setting, G-CSF has been widely studied in combination with horse ATG plus CsA. This regimen has not been shown to improve outcomes in several randomized trials [18, 19, 20] and the most recent European guidelines for the management of aplastic anemia only support the use of a short course of G-CSF in the setting of severe systemic infections, but advise against their routine use entirely 10]. A recent meta-analysis of 19 individual trials concluded that there was no impact on survival or response rate with the addition of these cytokines to standard immunosuppressive regimens .
TPO receptor agonists for aplastic anemia
Thrombopoietin (TPO) is the principal endogenous regulator of platelet production. TPO is a potent endogenous cytokine that binds to its receptor (c-Mpl) on megakaryocyte progenitors and stimulates a number of signal transduction events promoting megakaryocyte proliferation, and maturation and platelet release . TPO levels are greatly increased in aplastic anemia . Conversely, in immune thrombocytopenia (ITP) TPO levels are within the normal range or only moderately increased, and this finding suggested the utility of a TPO receptor agonist in this clinical condition [23, 24]. However, the regulation of endogenous TPO production is not yet fully understood. In the “sponge” model, following constitutive synthesis by the liver, TPO is passively regulated by its binding to TPO receptors on platelets and megakaryocytes .
Multiple lines of evidence support a pleiotropic role for TPO in hematopoiesis, beyond its obvious function as the primary endogenous factor controlling platelet production. First, TPO receptors are present on primitive hematopoietic stem and progenitor cells . Second, hematopoietic repopulating assays performed in mice support a role for TPO in hematopoietic stem cell survival, self-renewal, and expansion [27, 28]. Third, TPO/c-Mpl signaling in humans plays a role in regulating quiescent hematopoietic stem cells . Fourth, humans with bi-allelic mutations in c-Mpl develop congenital amegakaryocytic thrombocytopenia (CAMT); a disorder characterized by severe thrombocytopenia presenting shortly after birth. Patients with CAMT typically have absent or greatly diminished megakaryocytes in the bone marrow and are at high risk for developing aplastic anemia . Fifth, the equivalent Mpl knockout mouse model (Mpl(−/−)) demonstrates reduced numbers of hematopoietic stem and progenitor cells [27, 31, 32]. And finally, a homozygous nonsense mutation in the Mpl gene has been reported in association with familial aplastic anemia .
As expected, measurements of serum thrombopoietin levels of patients during the treatment were markedly elevated compared to healthy controls, but they remained unchanged over time. Analysis of leukocytes’ telomere length and immunophenotypic panel of T cell subsets were also unrevealing for significant differences pre- or post-eltrombopag, or between that of responders and nonresponders.
While strategies are ongoing investigating this agent in naïve patients with severe aplastic anemia, in moderate aplastic anemia and in myelodysplastic syndromes, ours is currently the only published study of the use of a TPO mimetic for acquired bone marrow failure.
TPO receptor agonists for thrombocytopenia in myelodysplastic syndromes
Preclinical research showing that eltrombopag stimulates megakaryopoiesis in patients with myelodysplastic syndromes (MDS), while potentially decreasing malignant cells  provide a rationale for testing TPO agonists in this setting. Furthermore, TPO levels are also elevated in MDS, but to a lesser extent as in aplastic anemia . Romiplostim has been tested in patients with lower risk MDS and thrombocytopenia . This single-arm study reported durable platelet responses in 46 % of patients with decreased bleeding events and platelet transfusion frequency. There were two cases (5 %) of progression to acute myeloid leukemia (AML) and four cases (9 %) of increases in blasts counts, which reversed on discontinuation of romiplostim. A subsequent randomized, double-blind, placebo controlled trial treating patients with low to intermediate risk-1 disease was terminated early due to more cases of AML progression in the treatment arm. In total 219 patients were randomized 2:1 to treatment with romiplostim (147 patients) to placebo (72 patients). There were 11 patients with progression to AML, 10 on the treatment arm versus 2 on the placebo arm, giving a hazard ratio (HR) of 2.51 for patients treated with romiplostim. Circulating myeloblast numbers increased to greater than 10 % in 28 patients, with 25 of these on the treatment arm. Eight of these patients were diagnosed with AML. A warning was subsequently added to the prescribing information, based on these results of increased blast cell counts and increased risk of progression to AML in patients with MDS. On long-term follow-up of this study published in abstract form and presented at ASH 2012 , however, two more cases of AML developed in the placebo arm that had not been included in the previous analysis; with a median follow-up of 17.8 months, AML rates were 8.9 % for romiplostim and 8.5 % for placebo with a HR of 1.2 for those on drug to progress to AML. Of interest, twelve of the 22 cases of AML were in patients who were RAEB-1.
Standard therapy for MDS includes hypomethylating agents and lenalidomide . These agents are effective with about half of patients responding but have significant toxicity and commonly cause cytopenias [43, 44]. Romiplostim has been used in combination with standard therapy for low-risk MDS in an attempt to reduce complications from thrombocytopenia and to prevent course delays or dose reductions. A phase 2 study investigated adding romiplostim to patients with low- or intermediate-risk MDS receiving azacytadine . Forty patients were randomized to either 500 or 750 μg of romiplostim or placebo subcutaneously once weekly during 4 cycles of azacytadine. There was no statistically significant difference in the primary endpoint of clinically significant thrombocytopenic events (CSTEs) defined as grade 3 or 4 thrombocytopenia (platelet count <50,000/μL), starting on day 15 of the first cycle or by a platelet transfusion at any time during the treatment period between groups although numbers were small. However, the higher dose of romiplostim did raise median platelet counts during cycle 3 on day 1 and at the nadir compared to placebo.
Romiplostim has been used in combination with the hypomethylating agent decitabine . Patients with low- or intermediate-risk MDS were randomized to either placebo or romiplostim at 750 μg. The primary endpoint was CSTEs as defined in the romiplostim/azacytadine study. Similar to that study the numbers were too small to detect significant differences between the groups although there were trends towards higher platelet counts at the beginning of treatment cycles, lower rates of platelet transfusion and less bleeding events in the romiplostim treated group. These two studies suggest a modest clinical benefit to combining hypomethylating agents with romiplostim with no added toxicity. Neither of these small studies were adequately powered to detect a significant difference between placebo and romiplostim treatment groups and larger clinical trials may be needed.
Lenalidomide therapy while useful in patients with low-risk MDS causes thrombocytopenia in 44–74 % of patients [47, 48], which may lead to dose reduction and treatment interruptions. Combination therapy with a TPO agonist could, hypothetically, result in improved outcomes if dosing schedules could be maintained. This approach was investigated in a phase 2, placebo controlled, multicenter study which randomized 39 patients with low or intermediate-1 risk MDS to placebo, romiplostim at 500 or 750 μg dose while receiving four cycles of lenalidomide . In the romiplostim groups, there was a trend towards higher percentage of patients achieving MDS treatment responses and lower percentage of patients who received transfusions during the four cycles. No romiplostim dose response was seen probably because of small numbers. There was a decreased risk of reduction or delay in lenalidomide dosing with 50 % of patients receiving placebo, 36 % in the 500 μg and 15 % in the 750 μg group requiring a reduction. This study also had too few patients to come to clear conclusions regarding the utility of combination therapy.
Preliminary data using eltrombopag in MDS have recently been reported orally and in abstract form at ASH 2012. Promising results were described from an ongoing Italian multicenter trial, which enrolled patients with low and intermediate-1 IPSS risk disease and platelet counts less than 30,000/μL . By exclusion criteria, patients were ineligible for or refractory to other treatments. Eltrombopag commenced at 50 mg and was increased every 2 weeks to a maximum of 300 mg. At a median follow-up of 6 months, five of ten patients on drug had had a complete response as defined by a platelet count greater than 100,000/μL and absence of bleeding. One patient in the treatment group had a response (R) defined as an increase in platelet count of ≥30,000/μL if baseline is >20,000/μL or if baseline <20,000/μL an increase of <20,000/μL and increase by at least 100 %, not due to transfusions. Just one patient had a response in the placebo arm and was called an ‘unstable response.’ There were no progressions in the treatment arm and one in the placebo arm. Eltrombopag has also been used in patients with advanced MDS, and preliminary results were presented in poster form at ASH 2012 by an independent group of investigators . 17 patients with advanced MDS (int-2 to high risk by WHO criteria) or AML with thrombocytopenia were treated with eltrombopag for 8 weeks with dose increases if no platelet response was seen. 24 % of patients had a response. In all 11 patients with post baseline bone marrow examinations there were no clinically meaningful increase in blasts from pre-treatment. As these results have yet to be published in a peer reviewed journal, the data should be regarded as preliminary and not definitive.
Risk of clonal evolution or progression
Patients with aplastic anemia have a rate of clonal evolution of about 15 % over 10 years . There is a concern that, as TPO agonists stimulate stem cells, they may also stimulate dysplastic or leukemic stem cells and precipitate or accelerate clonal evolution in these patients. Currently, it is unclear whether treatment with TPO receptor agonists may increase, or decrease, the risk of clonal evolution to myelodysplasia and leukemia in bone marrow failure. Despite the concern that some leukemia blast cells express TPO receptors, in vivo and in vitro studies thus far suggest eltrombopag inhibits proliferation of leukemic cells while continuing to stimulate megakaryopoiesis [38, 53, 54]. More clinical data are necessary to determine if this is more than just a theoretical risk. In the only published study using TPO agonists in aplastic anemia clonal evolution to monosomy 7 developed in 2 patients who did not have a response . Long-term follow-up data will be crucial to investigate whether this is a valid concern in this group of drugs. Routine utilization of these drugs to treat patients with aplastic anemia or MDS is premature and not advised: we strongly warn against their use in routine practice until there is more information on long-term outcomes and risks.
Current NIH protocols are testing eltrombopag in combination with immunosuppression for treatment-naïve severe aplastic anemia, and as a single agent in patients with moderate aplastic anemia and myelodysplastic syndrome. The majority of the hematologic responses observed following initial treatment with standard immunosuppression (h-ATG/CsA) for SAA are partial, with only a few patients achieving normal blood counts. The explanation for partial recovery and relapse are not fully understood, but incomplete elimination of auto-reactive T cells and insufficient stem cell reserve are both possible. Furthermore, 10–15 % of SAA patients treated with standard immunosuppression will eventually develop an abnormal karyotype, with monosomy 7 being most common, which portends progression to myelodysplasia and leukemia. Clonal evolution is less frequent in complete responders to immunosuppression. Although horse ATG/CsA represented a major advance in the treatment of SAA, refractoriness, incomplete responses, relapse, and clonal evolution limit the success of this modality. Thus, newer regimens are needed to address these limitations, and provide a better alternative to stem cell transplantation.
Conflict of interest
The authors declare that they have no conflicts of interest or competing financial or personal relationships that could inappropriately influence the content of this article.
- 7.Yamasaki M, Akagi K, Niinomi K, Kinoshita S, Kitawaki T, Yoshioka K. Intracranial hemorrhage associated with aplastic anemia. No to Hattatsu Brain Dev. 1989;21:215–21.Google Scholar
- 13.Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–14.PubMedCrossRefGoogle Scholar
- 16.Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, Musto P, Balleari E. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070–4.PubMedCrossRefGoogle Scholar
- 18.Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, et al: A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the EBMT. Blood; 2011. doi: 10.1182/blood-2010-08-304071.
- 19.Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, Sugita K, Yabe H, Ohara A, Tsukimoto I. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.PubMedGoogle Scholar
- 24.Hirayama Y, Sakamaki S, Matsunaga T, Kuga T, Kuroda H, Kusakabe T, Sasaki K, Fujikawa K, Kato J, Kogawa K, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood. 1998;92:46–52.PubMedGoogle Scholar
- 38.Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114:3899–908.PubMedCrossRefGoogle Scholar
- 41.Kantarjian HM, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Bennett JM, et al. Treatment with the thrombopoietin (tpo)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): Follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. Blood. 2012;120:8–11.CrossRefGoogle Scholar
- 45.Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116:3163–70.PubMedCrossRefGoogle Scholar
- 49.Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol. 2012;5:71.PubMedCrossRefGoogle Scholar
- 50.Oliva EN, Santini V, Zini G, Palumbo GA, Poloni A, Cortelezzi A, Voso MT, Molteni A, Sanpaolo G, Marino A, et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS). Blood. 2012;120:20.CrossRefGoogle Scholar
- 51.Mittelman M, Assouline S, Briasoulis E, Alonso A, Delgado RG, O’Gorman P, Kim HJ, Yoon S-S, Zaritskey A, Flynn CM, et al. Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-week open-label part of an ongoing study. ASH Annual Meeting Abstracts. 2012;120:3822–8.Google Scholar